Experimental study on interleukin 6 activity against tumor; Regulation of interleukin-2 induced lak cell activity

1993 ◽  
Vol 5 (4) ◽  
pp. 263-267
Author(s):  
Lisheng Lu ◽  
Zhengyan Cui ◽  
Ling Zhang ◽  
Denghua Li ◽  
Zhigang Tian
1990 ◽  
Vol 8 (7) ◽  
pp. 1269-1276 ◽  
Author(s):  
B G Redman ◽  
L Flaherty ◽  
T H Chou ◽  
A al-Katib ◽  
M Kraut ◽  
...  

Twenty-six patients with metastatic cancer were entered into a phase I trial of concurrent recombinant interleukin-2 (IL-2) and recombinant interferon-gamma (IFN-gamma). IL-2 was administered as a continuous intravenous infusion for 5 days. IFN-gamma was administered by a daily intramuscular (IM) injection during the 5 days of IL-2 administration. Treatment was repeated twice after 9-day rest periods. After a 2-week rest, patients without evidence of tumor progression were retreated. Natural killer (NK)- and lymphokine-activated killer (LAK)-cell activity were assayed in each patient before treatment, on day 1, and on day 5 of each cycle. Constitutional symptoms occurred in most patients but were not dose-limiting. Other toxicities included hypotension responsive to fluids, transient elevations in liver function tests, erythema/pruritus, eosinophilia, and transient leukopenia/thrombocytopenia. The maximum-tolerated dose (MTD) of the combination was 1 x 10(6) U/m2/d of IL-2 combined with 0.50 mg/m2/d of IFN-gamma. The dose-limiting toxicity was pulmonary manifesting as rales and shortness of breath. The dose of the combination that resulted in the optimal generation of in vivo LAK-cell activity was a dose of at least 0.25 mg/m2/d of IFN-gamma combined with 1 x 10(6) U/m2/d of IL-2. Objective clinical responses were seen in five of 26 patients. These included a partial response of 2 months duration in a patient with non-Hodgkin's lymphoma (NHL), mixed responses in a patient with NHL and two patients with renal cell carcinoma (RCC), and an ongoing assessable response in a patient with bone metastases from RCC. The recommended dose for phase II trials of this combination is 0.50 mg/m2 of IFN-gamma and 1 x 10(6) U of IL-2.


1995 ◽  
Vol 182 (3) ◽  
pp. 789-799 ◽  
Author(s):  
H Ullum ◽  
P C Gøtzsche ◽  
J Victor ◽  
E Dickmeiss ◽  
P Skinhøj ◽  
...  

Cytotoxicity mediated by natural killer (NK) and lymphokine-activated killer (LAK) cells may be of significance in host defense against viral infections. This study included 347 patients infected with human immunodeficiency syndrome virus (HIV) type 1 and 110 controls. The NK cell activity, either unstimulated or stimulated with interferon-alpha (IFN-alpha) or interleukin-2 (IL-2), and the LAK cell activity were suppressed in patients, but the NK/LAK cell activity did not differ between patients with AIDS and patients without AIDS. However, the IFN-alpha-stimulated NK cell activity and LAK cell activity were reduced in patients with symptoms of HIV disease (CDCIV) when compared with asymptomatic patients (CDCII+III). When the data were analyzed by multiple linear regression, the percentage of CD4+ cells had a positive effect on these two parameters in patients without AIDS, whereas the percentage of CD4+ cells had no significant effect on unstimulated and IL-2-stimulated NK cell activity in these patients. In controls and AIDS patients, the percentage of CD4+ cells had no effect on NK/LAK cell activity in multiple linear models. The total number of CD16+ cells was low in patients compared to controls, whereas the percentages of CD16+, CD56+, and CD16+CD56+ were either normal or elevated. Therefore, the decrease in NK cell subpopulations did not contribute to the observed depression in NK/LAK cell activity in vitro. It is concluded that natural immunity is suppressed in HIV-seropositive patients primarily because of a qualitative defect of the NK/LAK cells. This qualitative defect includes a reduced responsiveness to IFN-alpha, which is progressive until the onset of symptoms, and possibly related to the loss of CD4+ cells.


1988 ◽  
Vol 79 (9) ◽  
pp. 1497-1503
Author(s):  
Masamichi Hayakawa ◽  
Tadashi Hatano ◽  
Yuzo Koyama ◽  
Takeshi Masuda ◽  
Isao Higa ◽  
...  

1992 ◽  
Vol 32 (3) ◽  
pp. 209-214 ◽  
Author(s):  
Shigeaki Ishizaka ◽  
Makoto Kimoto ◽  
Tadasu Tsujii

1991 ◽  
Vol 27 (3) ◽  
pp. 199-204 ◽  
Author(s):  
Sunanda Basu ◽  
Ajit Sodhi ◽  
Sukh Mahendra Singh ◽  
Alaparthy Suresh

1995 ◽  
Vol 29 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Lucia de La Rocque ◽  
Mércia M. Campos ◽  
Beni Olej ◽  
Frederico Castilho ◽  
Isabella F. Mediano ◽  
...  

1993 ◽  
Vol 26 (2) ◽  
pp. 183-189
Author(s):  
Masamichi Hayakawa ◽  
Tadashi Hatano ◽  
Masami Oda ◽  
Kunio Yoshihara ◽  
Shinichiro Yoshi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document